Prevention of Cardiac Dysfunction During Breast Cancer Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.
Also called NCT03760588
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 138 participants
- Sponsor
- Registry
-
NCT03760588
-
- Other papers using this trial's data
- Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT03760588. Randomized; quadruple masking; primary purpose prevention. Start 2019-01-31 (actual); primary completion 2024-09-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention of Cardiac Dysfunction During Breast Cancer Therapy
- Acronym
- PRADAII
- Condition
- Breast Cancer Female
- Condition
- Heart Failure
- Intervention (Drug)
- Sacubitril/valsartan
- Lead sponsor
- Torbjorn Omland
- Collaborator
- University Hospital, Akershus
- Collaborator
- Oslo University Hospital
- Collaborator
- University Hospital of North Norway
- Collaborator
- St. Olavs Hospital
- Collaborator
- Helse Stavanger HF
- Collaborator
- Klinbeforsk
- Collaborator
- Norwegian Cancer Society
- Collaborator
- Novartis
Record details
- Record id
cardio:ct-nct03760588- Content hash
a1c1e8aca223fe86ce8108f4b0b90a8bbaa52cc51ec5c68b24affb4bcec48511